Reagent and application for differentiating ovarian endometriosis/ovarian cancer

A technology for endometriosis and ectopic disease, which is applied in biological tests, instruments, measuring devices, etc., to achieve the effect of improving accuracy, accurate treatment measures, and optimal treatment effects

Active Publication Date: 2022-02-22
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently, biomarkers with high sensitivity, specificity and clinical relevance are yet to be discovered

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Reagent and application for differentiating ovarian endometriosis/ovarian cancer
  • Reagent and application for differentiating ovarian endometriosis/ovarian cancer
  • Reagent and application for differentiating ovarian endometriosis/ovarian cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Screening for protein markers related to EM / OC / FEM

[0045] 1. Experimental materials

[0046] 1. Research sample

[0047] A total of 30 patients with three groups of disease types who were treated in the Obstetrics and Gynecology Department of Peking Union Medical College Hospital from January 2019 to January 2020 were collected and included. The basic information of the patients is shown in Table 1.

[0048] (1) Ovarian endometriosis group (EM group): 10 cases: The included patients did not receive endometriosis-related drug treatment for half a year before operation.

[0049] (2) Ovarian malignant tumor group (OC group): 10 cases: the pathology was consistent with epithelial ovarian cancer.

[0050] (3) Other benign tumors of the ovary (FEM group): 10 cases: Pathologically excluded complicated endometriosis.

[0051] Table 1 Basic information of the patient population screened by protein markers

[0052]

[0053] IQR: interquartile range;

[0054] #...

Embodiment 2

[0157] Example 2 Validation of protein markers

[0158] 1. Experimental materials

[0159] 1. Research sample

[0160] From January 2019 to January 2020, serum samples of 203 inpatients in the Department of Obstetrics and Gynecology of Peking Union Medical College Hospital were collected for protein marker verification, including 88 patients in the EM group, 90 patients in the FEM group, and 25 patients in the OC group. For example, the basic information of all included patients is shown in Table 6.

[0161] Sample inclusion criteria:

[0162] Inclusion criteria: a. Adnexal tumors or pelvic masses found by ultrasound results, suspicious EM or OC or unknown significance; b. Surgical treatment confirmed at Peking Union Medical College Hospital.

[0163] Exclusion criteria: a. Combined with other gynecological benign and malignant tumors; b. Clinically suspected malignant tumors; c. Other systemic malignant tumors or a history of malignant tumors; d. Pregnancy.

[0164] Table...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention relates to the field of biotechnology, in particular to a differential diagnosis reagent for ovarian endometriosis / ovarian cancer and its application. The invention provides a detection reagent for differential diagnosis of ovarian endometriosis / ovarian cancer, which includes a reagent for detecting the expression levels of CA125, SELL, LILRA3, IGKC and / or DSC2. The present invention provides a marker for the differential diagnosis of ovarian endometriosis / ovarian cancer, CA125, SELL, LILRA3, IGKC and / or DSC2, which can be used for the preparation of products for the differential diagnosis of EM / OC, which have specific identification Good performance and high sensitivity. The use of this product can improve the accuracy of clinical EM / OC differential diagnosis, so that patients can obtain more accurate treatment measures and better treatment effects.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a reagent for distinguishing ovarian endometriosis / ovarian cancer and its application. Background technique [0002] Endometriosis (endometriosis) is a common benign gynecological disorder characterized by the growth of functional endometrial glands and stroma outside the uterine cavity. About one in 10 women of reproductive age suffers from endometriosis. However, it occurs in approximately 50% of women seeking evaluation for infertility and is more prone to disease progression; it occurs in as much as 70% of women in pain. Endometriosis is a benign lesion histomorphologically, but it can exhibit tumor-like features such as invasion, implantation, and distant metastasis in biological behavior. The clinical manifestations of endometriosis are complicated and interfere with the normal life of patients, and severe cases can cause heavy psychological pressure. Early detection plays a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68G01N33/574
CPCG01N33/6893G01N33/57449G01N33/57484
Inventor 王姝陈倩刘阳钞晓培郎景和
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap